We believe that Phytomedicine will effectively treat previously unmet medical needs and improve the lives of patients, impacting public health across the world.
MGC embraces this by creating Phyto-Cannabinoids based medicine products and providing them in various markets. These products are registered for sale and leverage the Company’s own proprietary Medical Cannabis formula through clinical trials in Europe, Israel, and Australia. In addition, tertiary and supplementary revenue streams solidify our presence in the market.
This enables future Medical product sales across the European Union, Australia, and other geographies, following the requisite legal and regulatory approvals.
To be a global leader in Phytocannabinoid-based medicines within the biopharmaceutical industry.
MGC Pharma’s goal is to facilitate the transformation of Phytocannabinoids into true medicinal product pipelines, and to provide breakthrough solutions for prevalent global health issues to improve the quality of patients’ lives and contribute to improved public health. MGC Pharma aims to build a responsible and profitable industry wherever the company operates.
To create a global supply chain focused on creating high level products and improving the lives of patients, by developing ground-breaking treatments through innovative research across multiple markets.
MGC Pharma’s global market view ensures that the Company will be at the forefront of research and development in this exploding market, with the potential to supply our products to research efforts worldwide, and then to the markets that this research opens.
MGC Pharma has multiple revenue streams from diverse activities in various verticals within the emerging Cannabis market, high visibility in all important geographic arenas, and the experience and knowledge to encourage the building of a responsible and profitable industry wherever the company operates.